NHS

Boehringer Ingelheim announced that UK’s National Institute for Health and Care Excellence (NICE) has recommended company’s Vargatef (nintedanib) in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) within the National Health Service (NHS) in England and Wales.

The drug has been recommended to treat patients with NSCLC of adenocarcinoma histology, after first-line chemotherapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Boehringer Ingelheim solid tumour oncology medical head Dr Mehdi Shahidi said: "We are delighted with this announcement from NICE which represents an important milestone in the effort to extend survival for patients with adenocarcinoma of the lung following initial treatment with chemotherapy."

Nintedanib, in combination with docetaxel, is claimed to be the first and only triple angiokinase inhibitor available for EU patients with advanced NSCLC of adenocarcinoma histology, after first-line chemotherapy.

"Nintedanib is claimed to be the first and only triple angiokinase inhibitor available for EU patients with advanced NSCLC of adenocarcinoma histology, after first-line chemotherapy."

Vargetef was also approved for use without restriction within NHS Scotland, as per its licenced indication and is accepted by the Swedish Dental and Pharmaceutical Benefits Agency as a subsidised treatment of advanced lung cancer patients with adenocarcinoma in combination with docetaxel, after first-line chemotherapy.

The recommendations were based on the results of LUME-Lung 1 study trial that showed nintedanib plus docetaxel significantly prolonged progression-free survival compared with docetaxel alone for patients with adenocarcinoma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study also demonstrated that nintedanib plus docetaxel, significantly extended overall survival to beyond one year for patients with adenocarcinoma compared to docetaxel alone and it enabled one in four patients with adenocarcinoma to live for at least two years after first-line chemotherapy, according to the company.

In November 2014, EU approved Vargatef in combination with docetaxel to treat adult patients with locally advanced and metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology, after first-line chemotherapy.

See Also:

Image: Endobronchial radiation therapy for non-small cell lung cancer. Photo: courtesy of Tdvorak.